IPP Bureau
Cipla acquires stake in Clean Max Auriga Power
By IPP Bureau - December 16, 2021
Clean Max Auriga Power is a special purpose vehicle engaged in the business of production, supply and distribution of solar and wind or other renewable energy generation plant
Sun gets US FDA approval for generic amphotericin B injection
By IPP Bureau - December 16, 2021
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
U.S. FDA approves Bristol Myers Squibb’s Orencia
By IPP Bureau - December 16, 2021
Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant
Vakrangee partners with PharmEasy to deliver medicines to remote areas
By IPP Bureau - December 16, 2021
Vakrangee through its Nextgen Kendras and BharatEasy Mobile Superaap will now be able to provide medicines & healthcare services in remote areas of the country
Serial entrepreneur Sanjeev Dahiwadkar joins RaphaCure Board
By IPP Bureau - December 16, 2021
Dahiwadkar currently heads four technology companies- WipeOut Inc, Cognota Healthcare Technologies, IT Shastra India and Moringa Techsolv, which he has founded
Glamyo Health collaborates with DocKnee for orthopaedic surgeries
By IPP Bureau - December 16, 2021
After specialising in laparoscopy, proctology, urology, and cosmetic surgeries, Glamyo Health is now venturing into orthopaedic surgeries
Syngene extends contract with Amgen till 2026
By IPP Bureau - December 16, 2021
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
USFDA grants Orphan Drug Designation to Zydus’ novel compound to treat malaria
By IPP Bureau - December 16, 2021
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
NATCO Pharma to acquire Dash Pharmaceuticals
By IPP Bureau - December 15, 2021
The cash consideration for the acquisition is US$ 18 million.
NephroPlus raises US $ 24 mn in E round to fund expansion
By IPP Bureau - December 15, 2021
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Pfizer’s Covid-19 drug 90 % effective
By IPP Bureau - December 15, 2021
The data has been shared with the U.S.FDA as part of an ongoing rolling submission for Emergency Use Authorisation
CellCarta acquires Biogazelle to strengthen its genomic capabilities
By IPP Bureau - December 15, 2021
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
Lo.Li Pharma International seeks partners for Deplesin therapy
By IPP Bureau - December 15, 2021
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Biogen and TheraPanacea collaborate to advance digital health in neuroscience
By IPP Bureau - December 15, 2021
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Immatics and Bristol Myers Squibb enter exclusive license for TCR Bispecific programme
By IPP Bureau - December 15, 2021
Immatics to receive upfront payment of US $ 150 million and additional milestone payments of up to US $ 770 million plus tiered double-digit royalties on net product sales
